SCHEMBL334400

SCHEMBL334400

CC(CCC1CO1)OCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
HTT P42858 2/20 0.36
CTSL P07711 1/20 0.36
CTSB P07858 1/20 0.36
CTSK P43235 1/20 0.36
ALDH1A1 P00352 1/20 0.35
GLA P06280 1/20 0.35
CHRM2 P08172 2/20 0.35
CHRM4 P08173 2/20 0.35
CHRM5 P08912 2/20 0.35
CHRM1 P11229 2/20 0.35
CHRM3 P20309 2/20 0.35
MGLL Q99685 2/20 0.35
TSHR P16473 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16037744 0.79 TDP1 (0.42) MEN1KMT2ASLC6A2SLC6A4SLC6A3
SCHEMBL16037746 0.79 TDP1 (0.42) MEN1KMT2ASLC6A2SLC6A4SLC6A3
SCHEMBL16039808 0.79 TDP1 (0.42) MEN1KMT2ASLC6A2SLC6A4SLC6A3
SCHEMBL8477943 0.77 MEN1 (0.42) MEN1KMT2ASLC6A2SLC6A4SLC6A3
SCHEMBL6800327 0.74 ALDH1A1 (0.43) MEN1KMT2ASLC6A2SLC6A4SLC6A3
SCHEMBL7850044 0.74 TSHR (0.43) MEN1KMT2ATSHRMAPT
SCHEMBL10245222 0.74 TSHR (0.43) MEN1KMT2ATSHRMAPT
SCHEMBL14118736 0.74 BCHE (0.46) MEN1KMT2AHTTALDH1A1TSHR
SCHEMBL31727861 0.74 ALDH1A1 (0.39) MEN1KMT2ASLC6A2SLC6A4SLC6A3
SCHEMBL6133472 0.73 SLC6A2 (0.41) SLC6A2SLC6A4SLC6A3HTTCHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
EP-1985620-A1 10a-AZALIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2008-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 MEN1 2456/4885KMT2A 939/4885SLC6A2 4677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.